thiocolchicoside / Generic mfg. - LARVOL DELTA

Evolutionary conservation of ubiquitin-like protein urmylation as revealed by URM1 gene shuffle from archaea to yeast. (PubMed, Commun Biol) - "Thus, thioactivation of archaeal Urm1 and urmylation-like conjugation are conserved and exchangeable processes between Sulfolobus and Saccharomyces. Our survey underlines that Urm1 likely occupies a key role in the evolution of the ubiquitin-like protein family."

Journal • Targeted Protein Degradation

Therapeutic efficacy of thiocolchicoside-nonsteroidal anti-inflammatory drug combination in pain management: A systematic review and cross-sectional real-world study. (PubMed, World J Orthop) - "Evidence indicates that multimodal therapy, including parenteral TCC with NSAIDs, provides quicker and effective pain relief, reduces muscle spasms, and improves hand-to-floor distance compared to using NSAIDs or TCC alone."

Journal • Real-world evidence • Back Pain • Immunology • Lumbar Back Pain • Musculoskeletal Diseases • Musculoskeletal Pain • Pain • Rheumatology

Autoimmune Hypoglycemia in Type 2 Diabetes: A Case of Thiocolchicoside-Induced Steroid-Refractory Insulin Autoimmune Syndrome. (PubMed, Clin Diabetes) - No abstract available

Journal • Diabetes • Hypoglycemia • Immunology • Metabolic Disorders • Type 2 Diabetes Mellitus

One potential method of recycling expired thiocolchicoside drug is to use an environmental corrosion inhibitor for carbon steel in HCl. (PubMed, Sci Rep) - "DFT-based quantum chemical indices made further understanding of the inhibitory mechanism possible. Results gained for all techniques used are in good agreement."

Journal

MESOCOLO: Mesotherapy Treatment of Irritable Bowel Syndrome (clinicaltrials.gov) - P2 | N=27 | Active, not recruiting | Sponsor: Polyclinique de l'Europe | Trial completion date: Jan 2026 ➔ Jan 2027 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease

Chemopreventive effects of chitosan nanogel with thiocolchicoside and lauric acid in chemically induced oral carcinogenesis, in a rodent model. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "There was also a significant decrease in the expression of EGFR and VEGFR signaling molecules in the CTL nanogel-treated group (p < 0.05 level). CTL nanogel shows potent chemopreventive efficiency in reducing the occurrence and severity of 4NQO-induced oral cancer in Wistar rats, marking it a promising candidate for further investigation in cancer prevention strategies."

IO biomarker • Journal • Preclinical • Head and Neck Cancer • Oncology • Oral Cancer • Solid Tumor • BAX • BCL2 • CASP3 • CCND1 • CTNNB1 • RAC1 • TNFA

Efficacy and Safety of the Combination of Diclofenac and Thiocolchicoside in the Treatment of Low Back Pain and Other Conditions: Systematic Review of the Literature. (PubMed, Healthcare (Basel)) - "However, there is no clear evidence of its clinical superiority over other available treatments, due to study heterogeneity and potential biases. Rigorous, standardized research with larger sample sizes and consistent methodologies is essential to definitively establish the efficacy and safety of diclofenac-thiocolchicoside, providing clearer guidance for clinical decision-making."

Journal • Review • Back Pain • Gastrointestinal Disorder • Inflammation • Lumbar Back Pain • Musculoskeletal Diseases • Musculoskeletal Pain • Pain

Exploring structural and spectroscopic aspects, solvent effect (polar and non-polar) on electronic properties, topological insights, ADME and molecular docking study of thiocolchicoside: A promising candidate for antiviral and antitumor pharmacotherapy. (PubMed, Spectrochim Acta A Mol Biomol Spectrosc) - "Thiocolchicoside (TCS), a colchicine derivative, was analyzed using experimental and theoretical spectroscopic methods. ADME prediction shows that TCS has low GI absorption and no permeability across the BBB, with five hydrogen bond donors and ten acceptors. Molecular docking analysis confirmed TCS's biological activity, demonstrating binding affinities for COVID-19 main proteases 6LU7, spike protein 6VXX, and SMAD proteins 1U7V (SMAD4) and 1U7F (SMAD3) with binding energies of -9.52, -3.59, -5.18, and -5.85 kcal/mol, indicating its potential antiviral and antitumor effects."

Journal • Infectious Disease • Novel Coronavirus Disease • Oncology • SMAD3 • SMAD4

Revolutionizing Drug Delivery: A Design Professional's Approach to Drug-loaded Transferosomal Vesicles for Transdermal Use. (PubMed, Pharm Nanotechnol) - "The study concludes that formulation TDP-8, which incorporates 3g of Aloe vera leaf mucilage (AVLM) and lime oil (LO) as permeability enhancers, demonstrated favorable discharge characteristics. This indicates its potential as an effective transdermal delivery system for LXM and TCS, offering a promising substitute for pain and inflammation relief while minimizing gastric irritation. The study succeeded in developing and evaluating transferosomal transdermal patches for LXM and TCS, providing an alternative delivery method that minimizes gastric irritation."

Journal • Inflammation • Pain

Efficacy of Thiocolchicoside for Musculoskeletal Pain Management: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. (PubMed, J Clin Med) - " Although thiocolchicoside was found to significantly reduce patient-reported low back pain, the clinical impact was very small, as the pooled effect estimates were below the MID, and the overall certainty of evidence was very low. In light of the safety concerns raised by the European Medicine Agency, an in-depth analysis on the risk-benefit balance of thiocolchicoside is required."

Clinical • Journal • Retrospective data • Review • Back Pain • Lumbar Back Pain • Musculoskeletal Diseases • Musculoskeletal Pain • Pain

A Comparative Study of Skeletal Muscle Relaxant Effects of Thiocolchicoside, Diazepam and Their Combination in Wistar Rats Using the Rotarod Apparatus. (PubMed, Cureus) - "This indicates that the addition of THC did not potentiate the skeletal muscle relaxant activity of DIZ. Conclusion THC didn't show skeletal muscle relaxant properties in both doses and did not potentiate the activity of DIZ."

Journal • Preclinical • Back Pain • CNS Disorders • Immunology • Infertility • Mood Disorders • Movement Disorders • Musculoskeletal Pain • Neuralgia • Orthopedics • Pain • Parkinson's Disease • Rheumatoid Arthritis • Rheumatology • Sexual Disorders

Nicolau Syndrome Associated with Diclofenac Sodium and Thiocolchicoside Injection: A Case Report (EADV 2024) - "NS is a rare condition first described in 1925 following intramuscular bismuth injection to treat syphilis and has been reported to develop after intramuscular, subcutaneous, intravenous, intraarticular and subacromial injections of various drugs. NS is accompanied by dermatological symptoms such as a vivid reticular-type purplish patch and varying degrees of tissue loss and necrosis after injection. The diagnosis of NS is primarily based on the patient ’ s medical history, clinical findings and exclusion of other differential diagnoses."

Case report • Clinical • Anesthesia • Dermatology • Infectious Disease • Oncology • Pain • Vasculitis

QUALITY BY DESIGN-BASED DEVELOPMENT AND IN-VITRO EVALUATION OF DUAL RELEASE TABLET OF ETORICOXIB & THICHOLCHICOSIDE: A NOVEL CHRONOTHERAPEUTIC APPROACH FOR ARTHRITIS PAIN MANAGEMENT. (PubMed, Ann Pharm Fr) - "A high level of patient compliance is ensured through the current design as the patient does not need to get out of bed at night to take the medication."

Journal • Preclinical • Immunology • Musculoskeletal Pain • Pain • Rheumatology

Effectiveness of Mesotherapy in Post-COVID Pain Syndrome: Retrospective Cohort Study of 96 Patients. (PubMed, Clin Ther) - "While both mesotherapy and oral therapy offer benefits in reducing pain and alleviating neuropathic symptoms in post-COVID pain syndrome, mesotherapy stands out as an especially effective and well-tolerated treatment method, surpassing the efficacy of the oral alternative."

Journal • Retrospective data • Infectious Disease • Musculoskeletal Diseases • Musculoskeletal Pain • Neuralgia • Novel Coronavirus Disease • Pain • Respiratory Diseases

Extracorporeal ShockWave Treatment vs. mesotherapy in the treatment of myofascial syndromes: a clinical trial. (PubMed, Front Med (Lausanne)) - "A case-control study was conducted on 54 patients, who were randomized into 2 groups: group A, consisting of 27 patients, who were treated with 5 sessions of focal ESWT on a weekly basis; and group B, consisting of 27 patients, who underwent 5 sessions of mesotherapy with Thiocolchicoside fl 4 mg/2 mL and Mepivacaine fl 10 mg/1 mL on a weekly basis...The results showed that focal ESWT and Mesoterapy are two valid and effective treatment options in reducing algic symptoms and improving short- and long-term quality of life. However, the use of ESWTs, despite being mildly painful but tolerated, has been shown to be superior to mesotherapy in terms of pain reduction and increased functional capacity."

Journal • Fibromyalgia • Musculoskeletal Diseases • Musculoskeletal Pain • Pain

Development of Thermosensitive Liposome-Containing In-Situ Gel Systems for Intranasal Administration of Thiocolchicoside and In Vivo Evaluation in a Rabbit Model. (PubMed, Pharm Dev Technol) - "İn situ liposomal gels showed 1.5x higher blood concentration than control formula. In situ gels of liposomal THC formulations offer advantages over traditional nasal solutions, demonstrating comparable bioavailability to parenteral medication while also preserving the health of nasal mucosa cells."

Journal • Preclinical

Anticancer potential of thiocolchicoside and lauric acid loaded chitosan nanogel against oral cancer cell lines: a comprehensive study. (PubMed, Sci Rep) - "Furthermore, the nanogel's ability to modulate proapoptotic gene expression highlights its potential for targeted cancer therapy. This research contributes to the growing interest in Chitosan-based nanogels and their potential applications in cancer treatment."

IO biomarker • Journal • Preclinical • Head and Neck Cancer • Oncology • Oral Cancer • Solid Tumor • BCL2

A nanocomposite competent to overcome solubility and permeation issues of capsaicin and thiocolchicoside simultaneously in gout management: Fabrication of nanocubosomes. (PubMed, Saudi Pharm J) - "The findings of analgesic activity illustrated that the analgesic effects exhibited by test formulation may be associated with increased licking period and inhibition of prostaglandins level. In conclusion, the transdermal application of NCs co-loaded with CAP and TCS may be a promising delivery system for enhancing their bioavailability as well as synergistic analgesic and anti-inflammatory activity in gout management."

Journal • Gout • Inflammation • Inflammatory Arthritis • Pain • Rheumatology

MESOCOLO: Mesotherapy Treatment of Irritable Bowel Syndrome (clinicaltrials.gov) - P2 | N=27 | Active, not recruiting | Sponsor: Polyclinique de l'Europe | Not yet recruiting ➔ Active, not recruiting

Enrollment closed • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease

Evaluation of different substance combinations in a multiple-session mesotherapy protocol for the management of osteoarthritis in dogs: a retrospective study. (PubMed, J Am Vet Med Assoc) - "The combination used in MG, particularly combined with photobiomodulation, produced longer-lasting clinically significant results."

Journal • Retrospective data • Immunology • Orthopedics • Osteoarthritis • Pain • Rheumatology

MESOCOLO: Mesotherapy Treatment of Irritable Bowel Syndrome (clinicaltrials.gov) - P2 | N=27 | Not yet recruiting | Sponsor: Polyclinique de l'Europe

New P2 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease

Pain and Botulinum Toxin – Two Off-Label Botulinum Toxin Uses (TOXINS 2024) - "Over 9 months, she underwent various treatments, including physical therapy, radial shockwaves, and mesotherapy with NSAIDs (piroxicam) and a muscle relaxant (thiocolchicoside), with limited improvement. For the patient with plantar fasciitis (Case 2), the aim was to employ the muscle-relaxing properties of BoNT-A to reduce tension in the Achilles-plantar system. For the patient with lateral epicondylitis (Case 1), both muscle relaxing and pain-relieving effects of BoNT-A were harnessed with the increased availability of substance P."

Aesthetic Medicine • Anesthesia • Movement Disorders • Musculoskeletal Diseases • Musculoskeletal Pain • Pain

Effects of Potentially Inappropriate Medications in Older Patients with Gastrointestinal System Cancer. (PubMed, Medeni Med J) - "The most frequently used prescriptions among the 98 PIMs were gliclazide, hyoscine N-butylbromide, simethicone, diphenoxylate atropine, and thiocolchicoside. Chemotherapy toxicity may increase with PIM detected on diagnosis. We suggest that PIM is an important factor in predicting the side effects of chemotherapy and minimizing the adverse effects."

Journal • Gastrointestinal Cancer • Gastrointestinal Disorder • Oncology • Pain • Renal Disease

Anti-inflammatory activity of lauric acid, thiocolchicoside and thiocolchicoside-lauric acid formulation. (PubMed, Bioinformation) - "The percentage of proteinase inhibition activity of LA, TC, and a combination of TC-LA and the standard drug was 66.65%, 77.49%, 94.07%, and 69.83%, and IC50 of LA, TC, a combination of TC-LA and standard drug were35.5 µg/mL, 32.12 µg/mL, 24.35 µg/mL and 37.80 µg/mL, respectively. We found out that lauric acid, thiocolchicoside, and thiocolchicoside-lauric acid formulation exhibited significant anti-inflammatory activity."

Journal • Inflammation

The Efficacy and Safety of a Combination of Thiocolchicoside and Etoricoxib in Low Back Pain (ESCoTEL): A Randomized Active-Controlled Trial. (PubMed, Cureus) - "Conclusions Both DFC and TFC were comparable in efficacy and safety for the management of recent-onset LBP. However, significantly more subjects with very severe pain or functional disability showed improvement after 28 days when treated with DFC compared to TFC."

Journal • Back Pain • Lumbar Back Pain • Musculoskeletal Pain • Pain